![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Details:
Preliminary analysis indicated significant improvements were found in the Graminex® Flower Pollen Extract study group for multiple urinary incontinence quality of life indicators.
Lead Product(s): Graminex G63 Flower Pollen Extract,Norwegian Beta 1,3/1,6 Glucan
Therapeutic Area: Urology Product Name: Pollimmune
Highest Development Status: N/A Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022